The Interaction Myth
The Peptide Drug Interaction Nobody Warns You About
'Peptides don't have drug interactions' is half true. The half that's false has put people in operating rooms with full stomachs.
There's a claim that circulates constantly in this space: peptides don't have drug interactions.
It's half right. The mechanism behind most drug interactions genuinely doesn't apply to peptides, and that's a real advantage worth understanding.
The other half is wrong in a way that has changed how surgical teams prepare patients — and the fix depends entirely on something only you can do.
The half that's true
Start with how drug interactions normally work.
Peptides largely bypass this system.
They aren't broken down by those liver enzymes. They're broken down by proteases — the same class of enzyme covered in Article 3 — and proteases are a completely different proposition. They're everywhere: in your blood, on your blood vessel walls, in your kidneys, throughout your tissues. They're abundant and their capacity is enormous.
You can't meaningfully compete for a system like that. There's no bottleneck to crowd.
So the advantage is real: peptides rarely produce the kind of interaction that dominates drug labelling. Anyone who tells you that isn't making it up.
It's just not what "drug interaction" means.
The half that isn't
Peptides have pharmacodynamic interactions in abundance. And in one case, they have a pharmacokinetic interaction too — through a mechanism that has nothing to do with liver enzymes.
The stomach as an interaction site
GLP-1 receptor agonists slow gastric emptying. That isn't a side effect — it's part of how they work. Food stays in the stomach longer, you feel full longer, you eat less.
But your stomach is also where every pill you swallow begins its journey. Change how fast it empties and you've changed how every oral medication gets absorbed — how quickly it arrives, and sometimes how much arrives at all.
For most drugs this doesn't matter much — a later peak, but roughly the same total absorbed. For some it matters a great deal:
Narrow therapeutic index drugs — medications where the gap between too little and too much is small. Blood thinners, thyroid replacement, some heart and seizure medications. These are the drugs where a shift in absorption timing can move you outside the window that was carefully established for you.
Oral contraceptives. This one deserves specific mention because the class isn't uniform. Semaglutide's labelling indicates no clinically meaningful effect. Tirzepatide's carries a warning — and advises using a barrier method or a non-oral contraceptive for four weeks after starting and after each dose increase.
Same drug class. Different interaction profile. Which is a good demonstration that "peptides are fine" is too coarse a statement to be useful — these things have to be checked drug by drug, from the actual labelling.
The operating room
Here's the consequence that reached furthest.
Before surgery or any procedure involving sedation, you're told not to eat. The reason is specific: under anaesthesia you lose the reflexes that normally keep stomach contents out of your airway. An empty stomach is a safety requirement, and the fasting periods used are based on how long a normal stomach takes to clear.
A drug that slows gastric emptying can invalidate that assumption. A patient who followed the fasting instructions exactly may still have material in their stomach when the procedure begins.
This was recognized as GLP-1 use expanded, and professional bodies responded. Initial guidance in 2023 was cautious and broad — recommending that these medications be held before elective procedures, with different timing for daily and weekly formulations.
That guidance has since been refined. Later multi-society recommendations moved toward assessing individual risk rather than holding for everyone — considering factors like symptoms and dose stability, using a clear liquid diet in the period beforehand, and in some cases ultrasound to check the stomach directly before proceeding.
The refinement matters, and it's a good example of clinical guidance responding to accumulating evidence rather than staying frozen. But the underlying point didn't change, and it's the one to take away:
Your surgical team needs to know. All of this depends on them having the information.
Every version of this guidance — the cautious early one and the nuanced later one — begins with the clinician knowing what you're taking. Risk stratification isn't possible for a medication nobody mentioned.
This article is not telling you to hold or adjust any medication before a procedure. That's a decision for the team doing the procedure, and stopping a prescribed drug on your own carries its own risks. The action here is disclosure, not self-management.
The additive effects
Briefly, because these are more intuitive once you have the framework:
Glucose. Anything lowering blood sugar stacks with anything else lowering blood sugar. Combining a GLP-1 agonist with insulin or certain older diabetes medications raises hypoglycaemia risk enough that dose reductions are routinely recommended when they're combined.
Blood pressure. Compounds with vascular effects combine with blood pressure medication in the obvious direction.
Insulin sensitivity, in the other direction. Growth hormone reduces insulin sensitivity — it raises blood glucose. Anything that increases growth hormone output inherits that effect, which matters for anyone with diabetes or pre-diabetes and can work against the goals of their other medication.
And a reminder from Article 2: MK-677 is routinely grouped with peptides and isn't one. It is processed by the liver enzyme system described above, which means it has exactly the metabolic interaction potential that peptides largely avoid. Anyone who inherited "peptides don't have interactions" and applied it there has applied it to the one compound in the stack where it's least true.
The disclosure problem
There's a specific failure that makes all of this worse, and it's worth naming directly.
People disclose prescriptions. They're much less likely to disclose compounds bought outside that system — partly through embarrassment, partly because those compounds don't feel like medication in the way a prescription does. It came from a website, not a pharmacy. It's a "supplement," or a "research compound," or just something being tried.
Your body doesn't make that distinction. A compound that slows gastric emptying does so regardless of where it was purchased.
And the asymmetry runs the wrong way: the compounds least likely to be disclosed are the ones clinicians know least about. An anaesthetist knows the GLP-1 drugs. They may have no information at all about an unapproved peptide — which makes being told more important, not less.
What you have now
That's eight tools.
A name isn't a molecule. Small structural changes aren't small. These things get injected for a reason. One number governs the whole regulatory landscape. Real engineering closes every exit and pays for it somewhere. Fragments inherit an assumption, not an activity. More isn't more. And "no interactions" is half a sentence.
In the final article we put them to work. We'll take a protocol — the ordinary kind, the kind that circulates and gets followed — and take it apart line by line.
You'll find that you can do most of it yourself now. That was the point.
This article is educational and not medical advice. It does not recommend starting, stopping, or adjusting any medication. Clinical guidance on peptide medications around procedures has been revised more than once and continues to develop — your medical team works from current guidance and your specific situation. Decisions about any therapy belong with a qualified clinician who knows your history.